Back to results
US 9,650,649 B2Granted
LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors
AssigneeViratherapeutics GmbH
InventorsDorothee Von Laer, Tsanan Heimann
Life of this patent
Estimating the term…
Abstract
The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.
Claims11
A tumor-specific replication-competent vector construct comprising:
- a vesicular stomatitis virus (VSV) vector pseudotyped with glycoprotein GP of lymphocyte choriomeningitis virus (LCMV) (VSV-LCMV-GP pseudotype vector), wherein the vector comprises a gene coding for a glycoprotein GP of LCMV and the vector either lacks a functional gene coding for envelope protein G of VSV or the envelope protein G is replaced, wherein infection of cells with the replication-competent VSV-LCMV-GP pseudotype vector causes LCMV-GP to be encoded in the genome of a progeny viral particle and subsequently expressed on the surface of the progeny viral particle;
- and
- wherein tropism of the progeny viral particle is independent of an additional tumor-targeting element or transgene in the VSV-LCMV-GP pseudotype vector and wherein the progeny viral particle exhibits tumor-specific replication competence.
Dependencies are inferred from the claim text.